546
Views
31
CrossRef citations to date
0
Altmetric
Research Article

Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design

, , &
Pages 321-330 | Received 13 Jan 2012, Accepted 25 Mar 2012, Published online: 21 May 2012

References

  • Lang AE, Lozano AM. (1998). Parkinson’s disease. First of two parts. N Engl J Med, 339:1044–1053.
  • Schapira AH. (1999). Science, medicine, and the future: Parkinson’s disease. BMJ, 318:311–314.
  • Singh N, Pillay V, Choonara YE. (2007). Advances in the treatment of Parkinson’s disease. Prog Neurobiol, 81:29–44.
  • Moos T, Jensen PH. (2004). Absence of prostate apoptosis response-4 protein in substantia nigra of Parkinson’s disease autopsies. Acta Neuropathol, 107:23–26.
  • Kish SJ, Shannak K, Hornykiewicz O. (1988). Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med, 318:876–880.
  • Wu SS, Frucht SJ. (2005). Treatment of Parkinson’s disease: what’s on the horizon? CNS Drugs, 19:723–743.
  • Pahwa R, Koller WC. (1998). Advances in the treatment of Parkinson’s disease. Drugs Today, 34:95–105.
  • Zorc B, Ljubic M, Antolic S, Filipovic-Grcic J, Maysinger D et al. (1993). Macromolecular prodrugs. II. Esters of l-dopa and [alpha]-methyldopa. Int J Pharm, 99:135–143.
  • Whitney CM. (2007). Medications for Parkinson’s disease. Neurologist, 13:387–388.
  • Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev, 53:283–318.
  • Lockman PR, Mumper RJ, Khan MA, Allen DD. (2002). Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm, 28:1–13.
  • Costantino L, Tosi G, Ruozi B, Bondioli L, Vandelli MA et al. (2009). Colloidal systems for CNS drug delivery. In: Hari Shanker S (ed.). Progress in Brain Research. Elsevier:Melbourne, Australia, 35–69.
  • Anderson JM, Shive MS. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev, 28:5–24.
  • Konstantinos A. (2004). Pegylated Poly(Lactide) and Poly(Lactide-Co-Glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv, 1:321–333.
  • Fonseca C, Simões S, Gaspar R. (2002). Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release, 83:273–286.
  • Jain RA. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 21:2475–2490.
  • Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. (1999). PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release, 57:171–185.
  • Galindo-Rodriguez S, Allémann E, Fessi H, Doelker E. (2004). Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res, 21:1428–1439.
  • Budhian A, Siegel SJ, Winey KI. (2007). Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm, 336:367–375.
  • Davda J, Labhasetwar V. (2002). Characterization of nanoparticle uptake by endothelial cells. Int J Pharm, 233:51–59.
  • Box GEP, Wilson KB. (1951). On the experimental attainment of optimum conditions. J R Stat Soc Ser B Stat Methodol, 13:1–45.
  • Myers RH, Montgomery DC. (2009). Response Surface Methodology: Process and Product Optimization using Designed Experiments. New York: Wiley.
  • Box GEP, Hunter W, Hunter JS. (1978). Statistics for Experimenters: An Introduction to Design, Data Analysis and Model Building. New York: John Wiley and Sons.
  • Cochran WG, Cox GM. (1957). Experimental Designs. New York: John Wiley and Sons.
  • Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ et al. (1998). Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release, 50:31–40.
  • Illum L, Khan MA, Mak E, Davis SS. (1986). Evaluation of carrier capacity and release characteristics for poly( butyl 2-cyanoacrylate) nanoparticles. Int J Pharm, 30:17–28.
  • Song X, Zhao Y, Hou S, Xu F, Zhao R, He J et al. (2008). Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm, 69:445–453.
  • Feng SS, Mu L, Win KY, Huang G. (2004). Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem, 11:413–424.
  • Freytag T, Dashevsky A, Tillman L, Hardee GE, Bodmeier R. (2000). Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microspheres. J Control Release, 69:197–207.
  • Lewis GA, Mathieu D, Phan-Tan-Luu R. (1999). Pharmaceutical Experimental Design. New York: Markel Dekker.
  • Montgomery DC. (1999). Design and Analysis of Experiments. New York: John Wiley and Sons.
  • Higuchi T. (1963). Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 52:1145–1149.
  • Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 13:123–133.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.